Vanquish Oncology 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   2 Trials   5 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PAC-1 / Vanquish Oncology
NCT04589832: Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Terminated
1/2
6
US
PAC-1, Entrectinib
Arkadiusz Z. Dudek, MD, HealthPartners Regions Cancer Care and Frauenshuh Cancer Care Centers, Vanquish Oncology, Inc., Genentech, Inc., Midwest Melanoma Partnership
Uveal Melanoma
03/22
06/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PAC-1 / Vanquish Oncology
NCT04589832: Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Terminated
1/2
6
US
PAC-1, Entrectinib
Arkadiusz Z. Dudek, MD, HealthPartners Regions Cancer Care and Frauenshuh Cancer Care Centers, Vanquish Oncology, Inc., Genentech, Inc., Midwest Melanoma Partnership
Uveal Melanoma
03/22
06/22

Download Options